Collaborate Disseminate
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for bebtelovimab, a new monoclonal antibody designed to reduce risk of hospitalization and death from COVID-19. The approval comes weeks after the FDA halted use of p… Continue reading New Omicron-targeting antibody therapy for COVID authorized by FDA
Over the last couple of years, a novel cannabinoid has quietly grown in popularity. Delta-8 THC is similar to its more commonly known psychoactive cousin, delta-9 THC, but a legal loophole has led to its broad use across the United States despite safet… Continue reading What is delta-8 THC and is it a safe cannabis alternative?
The first oral treatment designed specifically for COVID-19 has been authorized for use in the United States by the Food and Drug Administration (FDA). Called Paxlovid, the treatment is currently recommended for those at high risk of severe COVID-19 an… Continue reading FDA authorizes first pill developed specifically to treat COVID-19
The first FDA-approved eye drops to treat age-related blurry near vision (presbyopia) has gone on sale in the US, offering a potential alternative to reading glasses for the estimated 128 million Americans affected by this common condition.Continue Rea… Continue reading First FDA-approved eye drops to replace reading glasses go on sale
Ahead of a U.S Food and Drug Administration advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19. The new data reveals the treatment is significantly less effecti… Continue reading Promising COVID-19 pill is less effective than initially reported
A new study published in the journal JAMA Neurology is reporting more than one in three patients trialing the recently approved Alzheimer’s drug aducanumab experienced brain swelling side effects. The data is the first from the controversial drug’s Phase 3 trials to be peer-reviewed and published.
Tags: Alzheimer’s Disease, Dementia, Drugs, FDA, New Atlas Audio
Continue reading New Alzheimer’s drug leads to brain swelling in one-third of patients
US regulators have authorized a third COVID-19 vaccine booster dose for all adults over the age of 18. The new recommendations simplify the health advice and infectious disease expert Anthony Fauci urges boosters for all those who are six months beyond… Continue reading All US adults now eligible for third dose of COVID-19 vaccine
After overcoming several manufacturing hurdles Novavax says its long-awaited COVID-19 vaccine is finally ready for mass distribution. Amid a flurry of applications being filed with regulatory agencies across the world, Indonesia has become the first co… Continue reading Novavax COVID-19 vaccine finally ready for rollout
Rochelle Walensky, director of the US Centers for Disease Control and Prevention (CDC), has formally endorsed an independent advisory panel’s recommendation to allow use of Pfizer’s COVID-19 vaccine in children aged between five and 11 years old. The e… Continue reading Pfizer COVID-19 vaccine approved for kids aged 5 to 11 in the US
In a long-awaited decision the US Food and Drug Administration (FDA) has approved “mix and match” COVID-19 vaccine boosters, meaning your third dose does not need to be the same vaccine brand as your primary course. Alongside this announcement the FDA … Continue reading FDA approves mixing different COVID-19 vaccine boosters